Apolipoprotein D

Last updated

APOD
Protein APOD PDB 2APD.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases APOD , Apod, apolipoprotein D
External IDs OMIM: 107740; MGI: 88056; HomoloGene: 1246; GeneCards: APOD; OMA:APOD - orthologs
Orthologs
SpeciesHumanMouse
Entrez

347

11815

Ensembl

ENSG00000189058

ENSMUSG00000022548

UniProt

P05090

P51910

RefSeq (mRNA)

NM_001647

NM_001301353
NM_001301354
NM_007470

RefSeq (protein)

NP_001638

NP_001288282
NP_001288283
NP_031496

Location (UCSC) Chr 3: 195.57 – 195.58 Mb Chr 16: 31.12 – 31.13 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Apolipoprotein D (ApoD) is a protein that in humans is encoded by the APOD gene. [5] [6] [7] Unlike other lipoproteins, which are mainly produced in the liver, apolipoprotein D is mainly produced in the brain and testes. [8] It is a 29 kDa glycoprotein discovered in 1963 as a component of the high-density lipoprotein (HDL) fraction of human plasma. [9] [10] It is the major component of human mammary cyst fluid. The human gene encoding it was cloned in 1986 and the deduced protein sequence revealed that ApoD is a member of the lipocalin family, small hydrophobic molecule transporters. [6] ApoD is 169 amino acids long, including a secretion peptide signal of 20 amino acids. It contains two glycosylation sites (aspargines 45 and 78) and the molecular weight of the mature protein varies from 20 to 32 kDa (see figure 1).

Contents

Rassart Figure 1 Rassart Figure 1.jpg
Rassart Figure 1

The resolved tertiary structure shows that ApoD is composed of 8 anti-parallel β-strands forming a hydrophobic cavity capable of receiving different ligands. [11] [12] ApoD also contains 5 cysteine residues, 4 of which are involved in intra-molecular disulfide bonds.

Function

Apolipoprotein D (ApoD) is a component of HDL that has no marked similarity to other apolipoprotein sequences. It has a high degree of homology to plasma retinol-binding protein and other members of the alpha 2 microglobulin protein superfamily of carrier proteins, also known as lipocalins. It is a glycoprotein of estimated molecular weight 33 KDa. Apo-D is closely associated with the enzyme lecithin-cholesterol acyltransferase (LCAT) - an enzyme involved in lipoprotein metabolism. [7] ApoD has also been shown to be an important link in the transient interaction between HDL and low-density lipoprotein (LDL) particles and between HDL particles and cells. [13]

Interactions and ligands

ApoD was shown to bind steroid hormones such as progesterone and pregnenolone with a relatively strong affinity, and to estrogens with a weaker affinity. [14] [15] Molecular modeling studies identified bilirubin, a breakdown product of heme, as a potential ligand. [11] Arachidonic acid (AA) was identified as an ApoD ligand with a much better affinity than that of progesterone or pregnenolone. [16] AA is the precursor of prostaglandins and leukotrienes, molecules that are involved in inflammation, platelet aggregation and cellular regulation. [17] A very poor binding between ApoD and cholesterol has also been observed. [18] Other ApoD ligands include E-3-methyl-2-hexenoic acid, a scent molecule present in body odor secretions; [19] retinoic acid, which is involved in cellular differentiation; and sphingomyelin and sphingolipids, which are major components of HDL and cell membranes. [20] The fact that apoD may bind such a large variety of ligands strongly support the hypothesis that it could be a multi-ligand, multi-functional protein.

Clinical significance

APOD is a biomarker of androgen insensitivity syndrome (AIS). APOD is an androgen up-regulated gene in normal scrotal fibroblast cells in comparison to labia majora cells in females with complete AIS (CAIS). [21] APOD is associated with neurological disorders and nerve injury, especially related to myelin sheath. APOD was shown to be elevated in a rat model of stroke. [8] APOD is elevated in patients with schizophrenia, bipolar disorder, and Alzheimer's disease. [8]

ApoD expression in cells and tissues

Analysis of the ApoD gene promoter region identified a large number of promoter regulatory elements, among which are response elements to steroids (such as estrogen and progesterone) and glucocorticoids. Response elements to fatty acids, acute phase proteins, serum, and to the immune factor NF-κB were also observed. [22] [23] [24] The presence of such a large number of regulatory sequences suggests that the regulation of its expression is very complex.

ApoD has been identified in 6 mammalian species as well as in chickens, [25] [26] fruit flies, [27] plants [28] and bacteria. [29] In humans, monkeys, rabbits and guinea pigs, ApoD is highly expressed in the nervous system (brain, cerebellum, and peripheral nerves). Otherwise, expression levels of ApoD vary largely from organ to organ and species to species, with humans displaying the most diverse expression of ApoD, and mice and rats almost exclusively expressing ApoD in the nervous system (see Figure 2).

Rassart Figure 2 Rassart Figure 2.jpg
Rassart Figure 2

ApoD concentration in human plasma varies between 5 and 23 mg/100 ml. [30] In the nervous system, the ApoD mRNA is expressed by fibroblasts, astrocytes and oligodendrocytes [31] [32] [33] As a glycoprotein with a peptide signal, ApoD is secreted. Yet it can also be actively reinternalized. The transmembrane glycoprotein Basigin (BSG; CD147) was identified as an ApoD receptor. [34] BSG is a membrane glycoprotein receptor, a member of the immunoglobulin family, involved in several pathologies such as cancer and Alzheimer's disease. [35]

Modulation of ApoD expression

Studies on several cell types have shown that ApoD expression can be induced by several stressing situations such as growth arrest, senescence, oxidative and inflammatory stresses. [23] [24] ApoD expression is also increased in several neuropathologies. ApoD expression is modulated in several pathologies such as HDL familial deficiency, Tangier disease, [36] [37] LCAT familial deficit [38] and type 2 diabetes. [39] It is overexpressed in numerous cancers, [40] including breast, [41] [42] ovary, prostate, [43] skin [44] [45] and central nervous system (CNS) cancer. In many cases, its expression is correlated with highly differentiated, non-invasive and non-metastatic state.

A role in lipid metabolism has been identified for ApoD by a study on transgenic (Tg) mice overexpressing human ApoD in the CNS. [46] These mice slowly develop a hepatic and muscular steatosis accompanied with insulin resistance. However, none of the Tg mice develop obesity nor diabetes. ApoD induced lipid accumulation is not due to de novo lipogenesis but rather from increased lipid uptake in response to prostaglandin overproduction. [47]

Plasma ApoD levels decrease significantly during normal uncomplicated pregnancy. ApoD is further decreased in women with excessive gestational weight gain and their newborns. In these women, the ApoD concentration was tightly associated with the lipid parameters. [48] In morbidly obese women (BMI over 40) adipose tissues, ApoD protein expression is positively correlated with parameters of metabolic health. ApoD-null female mice (mice in which the ApoD gene was inactivated) present progressive (up to 50%) bone volume reduction with aging. [49]

ApoD and the nervous system

Both ApoD and Apolipoprotein E (ApoE) protein levels increase drastically at the site of regeneration following a nerve crush injury in the rat. [50] [51] Similar observations have been made in rabbits, marmoset monkeys and in mice. [52] Elevated levels of ApoD were observed in the cerebrospinal fluid, hippocampus and cortex of human patients with Alzheimer's disease, cerebrovascular disease, motoneuron disease, meningoencephalitis and stroke. [53] ApoD expression is altered in plasma and post-mortem brains of patients with schizophrenia. [54] In patients with Parkinson's disease or with multiple sclerosis, ApoD expression is strongly increased in glial cells of the substantia nigra. [55] [56]

Niemann-Pick type C (NPC) is a genetic disorder affecting cholesterol transport that is accompanied by chronic progressive neurodegeneration. In animal models of NPC, ApoD expression is increased in the plasma and the brain. [57] In rats, ApoD expression increases in the hippocampus after enthorinal cortex lesioning. ApoD mRNA and protein increases in the ipsilateral region of hippocampus as early as 2 days post-lesion (DPL), remains high for 10 days and returns to normal after 14 DPL, a period considered necessary for a complete reinervation. [58] Similar results are obtained after injection of kainic acid, an analog of glutamic acid which causes a severe neurodegenerative injury in the hippocampus [59] or after experimentally-induced stoke. [60] [61] ApoD expression is also increased in the aging brain. [53] Altogether, these data suggest that ApoD plays an important role in neural preservation and protection.

Tg mice are less sensitive to oxidative stress induced by paraquat, a free oxygen radical generator, and present reduced lipid peroxidation levels. In contrast, apoD-null mice show increased sensitivity to oxidative stress, increased brain lipid peroxidation and impaired locomotor and learning abilities. Similar results have been observed in a drosophila model. [62] Mice infected with the human coronavirus OC43 develop encephalitis and inflammatory demyelination of the CNS, a disease very similar to multiple sclerosis. Tg mice infected with OC43 display increased survivability compared to control animals. [63] Tg mice treated with kainic acid show a significant reduction of inflammatory responses and a much stronger protection against apoptosis in the hippocampus than control animals. [64] ApoD-null mice crossed with APP-PS1 mice, a mouse model of Alzheimer's disease, displayed a 2-fold increase of hippocampal amyloid plaque load. In contrast, the progeny of Tg mice crossed with APP-PS1 mice displayed reduced hippocampal plaque load by 35%, and a 35% to 65% reduction of amyloid peptide levels. [65]

Notes

Related Research Articles

<span class="mw-page-title-main">Apolipoprotein</span> Proteins that bind lipids to transport them in body fluids

Apolipoproteins are proteins that bind lipids to form lipoproteins. They transport lipids in blood, cerebrospinal fluid and lymph.

<span class="mw-page-title-main">Apolipoprotein E</span> Cholesterol-transporting protein most notably implicated in Alzheimers disease

Apolipoprotein E (Apo-E) is a protein involved in the metabolism of fats in the body of mammals. A subtype is implicated in Alzheimer's disease and cardiovascular diseases. It is encoded in humans by the gene APOE.

<span class="mw-page-title-main">Apolipoprotein B</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein B (ApoB) is a protein that in humans is encoded by the APOB gene. Its measurement is commonly used to detect risk of atherosclerotic cardiovascular disease.

<span class="mw-page-title-main">Liver X receptor</span> Nuclear receptor

The liver X receptor (LXR) is a member of the nuclear receptor family of transcription factors and is closely related to nuclear receptors such as the PPARs, FXR and RXR. Liver X receptors (LXRs) are important regulators of cholesterol, fatty acid, and glucose homeostasis. LXRs were earlier classified as orphan nuclear receptors, however, upon discovery of endogenous oxysterols as ligands they were subsequently deorphanized.

<span class="mw-page-title-main">Cholesterol 7 alpha-hydroxylase</span> Protein-coding gene in the species Homo sapiens

Cholesterol 7 alpha-hydroxylase also known as cholesterol 7-alpha-monooxygenase or cytochrome P450 7A1 (CYP7A1) is an enzyme that in humans is encoded by the CYP7A1 gene which has an important role in cholesterol metabolism. It is a cytochrome P450 enzyme, which belongs to the oxidoreductase class, and converts cholesterol to 7-alpha-hydroxycholesterol, the first and rate limiting step in bile acid synthesis.

<span class="mw-page-title-main">Lipocalin</span> Protein family

The lipocalins are a family of proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids, and lipids, and most lipocalins are also able to bind to complexed iron as well as heme. They share limited regions of sequence homology and a common tertiary structure architecture. This is an eight stranded antiparallel beta barrel with a repeated + 1 topology enclosing an internal ligand binding site.

<span class="mw-page-title-main">Apolipoprotein AI</span> Protein used in lipid metabolism

Apolipoprotein AI(Apo-AI) is a protein that in humans is encoded by the APOA1 gene. As the major component of high-density lipoprotein (HDL) particles, it has a specific role in lipid metabolism.

<span class="mw-page-title-main">Apolipoprotein C-III</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein C-III also known as apo-CIII, and apolipoprotein C3, is a protein that in humans is encoded by the APOC3 gene. Apo-CIII is secreted by the liver as well as the small intestine, and is found on triglyceride-rich lipoproteins such as chylomicrons, very low density lipoprotein (VLDL), and remnant cholesterol.

<span class="mw-page-title-main">Apolipoprotein C-IV</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein C-IV, also known as apolipoprotein C4, is a protein that in humans is encoded by the APOC4 gene.

<span class="mw-page-title-main">Low-density lipoprotein receptor-related protein 8</span> Cell surface receptor, part of the low-density lipoprotein receptor family

Low-density lipoprotein receptor-related protein 8 (LRP8), also known as apolipoprotein E receptor 2 (ApoER2), is a protein that in humans is encoded by the LRP8 gene. ApoER2 is a cell surface receptor that is part of the low-density lipoprotein receptor family. These receptors function in signal transduction and endocytosis of specific ligands. Through interactions with one of its ligands, reelin, ApoER2 plays an important role in embryonic neuronal migration and postnatal long-term potentiation. Another LDL family receptor, VLDLR, also interacts with reelin, and together these two receptors influence brain development and function. Decreased expression of ApoER2 is associated with certain neurological diseases.

<span class="mw-page-title-main">ABCA1</span> Mammalian protein found in Homo sapiens

ATP-binding cassette transporter ABCA1, also known as the cholesterol efflux regulatory protein (CERP) is a protein which in humans is encoded by the ABCA1 gene. This transporter is a major regulator of cellular cholesterol and phospholipid homeostasis.

<span class="mw-page-title-main">APOA5</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein A-V is a protein that in humans is encoded by the APOA5 gene on chromosome 11. It is significantly expressed in liver. The protein encoded by this gene is an apolipoprotein and an important determinant of plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of several lipoprotein fractions including VLDL, HDL, chylomicrons. It is believed that apoA-V affects lipoprotein metabolism by interacting with LDL-R gene family receptors. Considering its association with lipoprotein levels, APOA5 is implicated in metabolic syndrome. The APOA5 gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.

<span class="mw-page-title-main">Apolipoprotein A-II</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein A-II is a protein that in humans is encoded by the APOA2 gene. It is the second most abundant protein of the high density lipoprotein particles. The protein is found in plasma as a monomer, homodimer, or heterodimer with apolipoprotein D. ApoA-II regulates many steps in HDL metabolism, and its role in coronary heart disease is unclear. Remarkably, defects in this gene may result in apolipoprotein A-II deficiency or hypercholesterolemia.

<span class="mw-page-title-main">APOA4</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein A-IV is plasma protein that is the product of the human gene APOA4.

<span class="mw-page-title-main">Serum amyloid A1</span> Protein-coding gene in the species Homo sapiens

Serum amyloid A1 (SAA1) is a protein that in humans is encoded by the SAA1 gene. SAA1 is a major acute-phase protein mainly produced by hepatocytes in response to infection, tissue injury and malignancy. When released into blood circulation, SAA1 is present as an apolipoprotein associated with high-density lipoprotein (HDL). SAA1 is a major precursor of amyloid A (AA), the deposit of which leads to inflammatory amyloidosis.

<span class="mw-page-title-main">GPLD1</span> Protein-coding gene in the species Homo sapiens

Phosphatidylinositol-glycan-specific phospholipase D is an enzyme that in humans is encoded by the GPLD1 gene.

<span class="mw-page-title-main">APOM</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein M is an apolipoprotein and member of the lipocalin protein family that in humans is encoded by the APOM gene. It is found associated with high density lipoproteins and to a lesser extent with low density lipoproteins and triglyceride-rich lipoproteins. The encoded protein is secreted through the plasma membrane but remains membrane-bound, where it is involved in lipid transport. Two transcript variants encoding two different isoforms have been found for this gene, but only one of them has been fully characterized. It lacks an external amphipathic motif and is uniquely secreted to plasma without cleavage of its terminal signal peptide. The average molecular weight is 21253 Da, and the monoisotopic molecular weight is 21239 Da.

<span class="mw-page-title-main">Apolipoprotein L1</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein L1 is a protein that in humans is encoded by the APOL1 gene. Two transcript variants encoding two different isoforms have been found for this gene.

<span class="mw-page-title-main">ABCA7</span> Protein-coding gene in the species Homo sapiens

ATP-binding cassette sub-family A member 7 is a protein that in humans is encoded by the ABCA7 gene.

<span class="mw-page-title-main">APOF</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein F is a protein that in humans is encoded for by the APOF gene. The product of this gene is one of the minor apolipoproteins found in plasma. This protein forms complexes with lipoproteins and may be involved in transport and/or esterification of cholesterol.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000189058 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000022548 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ Drayna DT, McLean JW, Wion KL, Trent JM, Drabkin HA, Lawn RM (June 1987). "Human apolipoprotein D gene: gene sequence, chromosome localization, and homology to the alpha 2u-globulin superfamily". DNA. 6 (3): 199–204. doi:10.1089/dna.1987.6.199. PMID   2439269.
  6. 1 2 Drayna D, Fielding C, McLean J, Baer B, Castro G, Chen E, et al. (December 1986). "Cloning and expression of human apolipoprotein D cDNA". The Journal of Biological Chemistry. 261 (35): 16535–9. doi: 10.1016/S0021-9258(18)66599-8 . PMID   3453108.
  7. 1 2 "Entrez Gene: APOD apolipoprotein D".
  8. 1 2 3 Muffat J, Walker DW (January 2010). "Apolipoprotein D: an overview of its role in aging and age-related diseases". Cell Cycle. 9 (2): 269–73. doi:10.4161/cc.9.2.10433. PMC   3691099 . PMID   20023409.
  9. ↑ Ayrault Jarrier M, Levy G, Polonovski J (August 1963). "[Study of Human Serum Alpha-Lipoproteins by Immunoelectrophoresis]". Bulletin de la Société de Chimie Biologique. 45: 703–13. PMID   14051455.
  10. ↑ McConathy WJ, Alaupovic P (February 1976). "Studies on the isolation and partial characterization of apolipoprotein D and lipoprotein D of human plasma". Biochemistry. 15 (3): 515–20. doi:10.1021/bi00648a010. PMID   56198.
  11. 1 2 Peitsch MC, Boguski MS (February 1990). "Is apolipoprotein D a mammalian bilin-binding protein?". The New Biologist. 2 (2): 197–206. PMID   2083249.
  12. ↑ Eichinger A, Nasreen A, Kim HJ, Skerra A (October 2007). "Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D". The Journal of Biological Chemistry. 282 (42): 31068–75. doi: 10.1074/jbc.M703552200 . PMID   17699160. S2CID   9647650.
  13. ↑ Braesch-Andersen S, Beckman L, Paulie S, Kumagai-Braesch M (December 2014). "ApoD mediates binding of HDL to LDL and to growing T24 carcinoma". PLOS ONE. 9 (12): e115180. Bibcode:2014PLoSO...9k5180B. doi: 10.1371/journal.pone.0115180 . PMC   4267786 . PMID   25513803.
  14. ↑ Pearlman WH, Guériguian JL, Sawyer ME (August 1973). "A specific progesterone-binding component of human breast cyst fluid". The Journal of Biological Chemistry. 248 (16): 5736–41. doi: 10.1016/S0021-9258(19)43566-7 . PMID   4723913.
  15. ↑ Lea OA (October 1988). "Binding properties of progesterone-binding Cyst protein, PBCP". Steroids. 52 (4): 337–8. doi:10.1016/0039-128x(88)90135-3. PMID   3250014. S2CID   26492300.
  16. ↑ Morais Cabral JH, Atkins GL, Sánchez LM, López-Boado YS, López-Otin C, Sawyer L (June 1995). "Arachidonic acid binds to apolipoprotein D: implications for the protein's function". FEBS Letters. 366 (1): 53–6. Bibcode:1995FEBSL.366...53M. doi: 10.1016/0014-5793(95)00484-q . PMID   7789516. S2CID   9063157.
  17. ↑ Kuehl FA J, Egan RW (28 November 1980). "Prostaglandins, arachidonic acid, and inflammation". Science. 210 (4473): 978–84. Bibcode:1980Sci...210..978K. doi:10.1126/science.6254151. PMID   6254151.
  18. ↑ Patel RC, Lange D, McConathy WJ, Patel YC, Patel SC (June 1997). "Probing the structure of the ligand binding cavity of lipocalins by fluorescence spectroscopy". Protein Engineering. 10 (6): 621–5. doi: 10.1093/protein/10.6.621 . PMID   9278274.
  19. ↑ Zeng C, Spielman AI, Vowels BR, Leyden JJ, Biemann K, Preti G (June 1996). "A human axillary odorant is carried by apolipoprotein D". Proceedings of the National Academy of Sciences of the United States of America. 93 (13): 6626–30. Bibcode:1996PNAS...93.6626Z. doi: 10.1073/pnas.93.13.6626 . PMC   39076 . PMID   8692868.
  20. ↑ Breustedt DA, Schönfeld DL, Skerra A (February 2006). "Comparative ligand-binding analysis of ten human lipocalins". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1764 (2): 161–73. doi:10.1016/j.bbapap.2005.12.006. PMID   16461020.
  21. ↑ Appari M, Werner R, Wünsch L, Cario G, Demeter J, Hiort O, et al. (June 2009). "Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome". Journal of Molecular Medicine. 87 (6): 623–32. doi:10.1007/s00109-009-0462-3. PMC   5518750 . PMID   19330472.
  22. ↑ Lambert J, Provost PR, Marcel YL, Rassart E (20 February 1993). "Structure of the human apolipoprotein D gene promoter region". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1172 (1–2): 190–2. doi:10.1016/0167-4781(93)90292-l. PMID   7916629.
  23. 1 2 Do Carmo S, Séguin D, Milne R, Rassart E (15 February 2002). "Modulation of apolipoprotein D and apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter". The Journal of Biological Chemistry. 277 (7): 5514–23. doi: 10.1074/jbc.M105057200 . PMID   11711530. S2CID   45692527.
  24. 1 2 Do Carmo S, Levros LC J, Rassart E (June 2007). "Modulation of apolipoprotein D expression and translocation under specific stress conditions". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1773 (6): 954–69. doi: 10.1016/j.bbamcr.2007.03.007 . PMID   17477983.
  25. ↑ Vieira AV, Lindstedt K, Schneider WJ, Vieira PM (December 1995). "Identification of a circulatory and oocytic avian apolipoprotein D". Molecular Reproduction and Development. 42 (4): 443–6. doi:10.1002/mrd.1080420411. PMID   8607974. S2CID   34209685.
  26. ↑ Ganfornina MD, Sánchez D, Pagano A, Tonachini L, Descalzi-Cancedda F, Martínez S (January 2005). "Molecular characterization and developmental expression pattern of the chicken apolipoprotein D gene: implications for the evolution of vertebrate lipocalins". Developmental Dynamics. 232 (1): 191–9. doi: 10.1002/dvdy.20193 . PMID   15580625. S2CID   14396229.
  27. ↑ Sánchez D, Ganfornina MD, Torres-Schumann S, Speese SD, Lora JM, Bastiani MJ (June 2000). "Characterization of two novel lipocalins expressed in the Drosophila embryonic nervous system". The International Journal of Developmental Biology. 44 (4): 349–59. PMID   10949044.
  28. ↑ Frenette Charron JB, Breton G, Badawi M, Sarhan F (24 April 2002). "Molecular and structural analyses of a novel temperature stress-induced lipocalin from wheat and Arabidopsis". FEBS Letters. 517 (1–3): 129–32. Bibcode:2002FEBSL.517..129F. doi:10.1016/s0014-5793(02)02606-6. PMID   12062422. S2CID   34705682.
  29. ↑ Bishop RE, Penfold SS, Frost LS, Höltje JV, Weiner JH (29 September 1995). "Stationary phase expression of a novel Escherichia coli outer membrane lipoprotein and its relationship with mammalian apolipoprotein D. Implications for the origin of lipocalins". The Journal of Biological Chemistry. 270 (39): 23097–103. doi: 10.1074/jbc.270.39.23097 . PMID   7559452. S2CID   2904679.
  30. ↑ Camato R, Marcel YL, Milne RW, Lussier-Cacan S, Weech PK (June 1989). "Protein polymorphism of a human plasma apolipoprotein D antigenic epitope". Journal of Lipid Research. 30 (6): 865–75. doi: 10.1016/S0022-2275(20)38304-8 . PMID   2477480.
  31. ↑ Smith KM, Lawn RM, Wilcox JN (June 1990). "Cellular localization of apolipoprotein D and lecithin:cholesterol acyltransferase mRNA in rhesus monkey tissues by in situ hybridization". Journal of Lipid Research. 31 (6): 995–1004. doi: 10.1016/S0022-2275(20)42739-7 . PMID   2373967.
  32. ↑ Provost PR, Marcel YL, Milne RW, Weech PK, Rassart E (23 September 1991). "Apolipoprotein D transcription occurs specifically in nonproliferating quiescent and senescent fibroblast cultures". FEBS Letters. 290 (1–2): 139–41. Bibcode:1991FEBSL.290..139P. doi: 10.1016/0014-5793(91)81244-3 . PMID   1915865. S2CID   20185401.
  33. ↑ Provost PR, Villeneuve L, Weech PK, Milne RW, Marcel YL, Rassart E (December 1991). "Localization of the major sites of rabbit apolipoprotein D gene transcription by in situ hybridization". Journal of Lipid Research. 32 (12): 1959–70. doi: 10.1016/S0022-2275(20)41899-1 . PMID   1816324.
  34. ↑ Najyb O, Brissette L, Rassart E (26 June 2015). "Apolipoprotein D Internalization Is a Basigin-dependent Mechanism". The Journal of Biological Chemistry. 290 (26): 16077–87. doi: 10.1074/jbc.M115.644302 . PMC   4481210 . PMID   25918162.
  35. ↑ Iacono KT, Brown AL, Greene MI, Saouaf SJ (December 2007). "CD147 immunoglobulin superfamily receptor function and role in pathology". Experimental and Molecular Pathology. 83 (3): 283–95. doi:10.1016/j.yexmp.2007.08.014. PMC   2211739 . PMID   17945211.
  36. ↑ Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, et al. (August 1999). "The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease". Nature Genetics. 22 (4): 347–51. doi:10.1038/11914. PMID   10431237. S2CID   26890624.
  37. ↑ Alaupovic P, Schaefer EJ, McConathy WJ, Fesmire JD, Brewer HB J (August 1981). "Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease)". Metabolism: Clinical and Experimental. 30 (8): 805–9. doi:10.1016/0026-0495(81)90027-5. PMID   6790903.
  38. ↑ Albers JJ, Adolphson J, Chen CH, Murayama N, Honma S, Akanuma Y (9 July 1985). "Defective enzyme causes lecithin-cholesterol acyltransferase deficiency in a Japanese kindred". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 835 (2): 253–7. doi:10.1016/0005-2760(85)90280-2. PMID   4005283.
  39. ↑ Baker WA, Hitman GA, Hawrami K, McCarthy MI, Riikonen A, Tuomilehto-Wolf E, et al. (December 1994). "Apolipoprotein D gene polymorphism: a new genetic marker for type 2 diabetic subjects in Nauru and south India". Diabetic Medicine. 11 (10): 947–52. doi:10.1111/j.1464-5491.1994.tb00252.x. PMID   7895459. S2CID   24833816.
  40. ↑ Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE (1 March 2001). "Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers". Cancer Research. 61 (5): 1833–8. PMID   11280733.
  41. ↑ Díez-Itza I, Vizoso F, Merino AM, Sánchez LM, Tolivia J, Fernández J, et al. (February 1994). "Expression and prognostic significance of apolipoprotein D in breast cancer". The American Journal of Pathology. 144 (2): 310–20. PMC   1887137 . PMID   8311115.
  42. ↑ Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, et al. (2009). "Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients". Acta Oncologica. 48 (4): 514–21. doi: 10.1080/02841860802620613 . PMID   19107621. S2CID   22404040.
  43. ↑ Aspinall JO, Bentel JM, Horsfall DJ, Haagensen DE, Marshall VR, Tilley WD (August 1995). "Differential expression of apolipoprotein-D and prostate specific antigen in benign and malignant prostate tissues". The Journal of Urology. 154 (2 Pt 1): 622–8. doi:10.1097/00005392-199508000-00082. PMID   7541868.
  44. ↑ Miranda E, Vizoso F, Martín A, Quintela I, Corte MD, Seguí ME, et al. (June 2003). "Apolipoprotein D expression in cutaneous malignant melanoma". Journal of Surgical Oncology. 83 (2): 99–105. doi:10.1002/jso.10245. PMID   12772203. S2CID   25700567.
  45. ↑ West RB, Harvell J, Linn SC, Liu CL, Prapong W, Hernandez-Boussard T, et al. (August 2004). "Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans". The American Journal of Surgical Pathology. 28 (8): 1063–9. doi:10.1097/01.pas.0000126857.86186.4c. PMID   15252314. S2CID   5773777.
  46. ↑ Do Carmo S, Fournier D, Mounier C, Rassart E (April 2009). "Human apolipoprotein D overexpression in transgenic mice induces insulin resistance and alters lipid metabolism". American Journal of Physiology. Endocrinology and Metabolism. 296 (4): E802-11. doi:10.1152/ajpendo.90725.2008. PMID   19176353.
  47. ↑ Desmarais F, Bergeron KF, Rassart E, Mounier C (April 2019). "Apolipoprotein D overexpression alters hepatic prostaglandin and omega fatty acid metabolism during the development of a non-inflammatory hepatic steatosis" (PDF). Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1864 (4): 522–531. doi:10.1016/j.bbalip.2019.01.001. PMID   30630053. S2CID   58594626.
  48. ↑ Do Carmo S, Forest JC, Giguère Y, Masse A, Lafond J, Rassart E (2 September 2009). "Modulation of Apolipoprotein D levels in human pregnancy and association with gestational weight gain". Reproductive Biology and Endocrinology. 7: 92. doi: 10.1186/1477-7827-7-92 . PMC   3224896 . PMID   19723339.
  49. ↑ Martineau C, Najyb O, Signor C, Rassart É, Moreau R (September 2016). "Apolipoprotein D deficiency is associated to high bone turnover, low bone mass and impaired osteoblastic function in aged female mice". Metabolism: Clinical and Experimental. 65 (9): 1247–58. doi:10.1016/j.metabol.2016.05.007. PMC   7094319 . PMID   27506732.
  50. ↑ Boyles JK, Notterpek LM, Anderson LJ (15 October 1990). "Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I". The Journal of Biological Chemistry. 265 (29): 17805–15. doi: 10.1016/S0021-9258(18)38235-8 . PMID   2120218.
  51. ↑ Boyles JK, Notterpek LM, Wardell MR, Rall SC J (December 1990). "Identification, characterization, and tissue distribution of apolipoprotein D in the rat". Journal of Lipid Research. 31 (12): 2243–56. doi: 10.1016/S0022-2275(20)42112-1 . PMID   2090718.
  52. ↑ Ganfornina MD, Do Carmo S, Martínez E, Tolivia J, Navarro A, Rassart E, et al. (15 August 2010). "ApoD, a glia-derived apolipoprotein, is required for peripheral nerve functional integrity and a timely response to injury". Glia. 58 (11): 1320–34. doi:10.1002/glia.21010. PMC   7165554 . PMID   20607718.
  53. 1 2 Terrisse L, Poirier J, Bertrand P, Merched A, Visvikis S, Siest G, et al. (October 1998). "Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients". Journal of Neurochemistry. 71 (4): 1643–50. doi: 10.1046/j.1471-4159.1998.71041643.x . PMID   9751198. S2CID   24675226.
  54. ↑ Thomas EA, Dean B, Pavey G, Sutcliffe JG (27 March 2001). "Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders". Proceedings of the National Academy of Sciences of the United States of America. 98 (7): 4066–71. Bibcode:2001PNAS...98.4066T. doi: 10.1073/pnas.071056198 . PMC   31180 . PMID   11274430.
  55. ↑ Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F, et al. (1 October 2001). "Increased intrathecal production of apolipoprotein D in multiple sclerosis". Journal of Neuroimmunology. 119 (2): 327–32. doi:10.1016/s0165-5728(01)00378-2. PMID   11585636. S2CID   24583456.
  56. ↑ Ordoñez C, Navarro A, Perez C, Astudillo A, Martínez E, Tolivia J (April 2006). "Apolipoprotein D expression in substantia nigra of Parkinson disease". Histology and Histopathology. 21 (4): 361–6. doi:10.14670/HH-21.361. PMID   16437381.
  57. ↑ Yoshida K, Cleaveland ES, Nagle JW, French S, Yaswen L, Ohshima T, et al. (October 1996). "Molecular cloning of the mouse apolipoprotein D gene and its upregulated expression in Niemann-Pick disease type C mouse model". DNA and Cell Biology. 15 (10): 873–82. doi:10.1089/dna.1996.15.873. PMID   8892759.
  58. ↑ Terrisse L, Séguin D, Bertrand P, Poirier J, Milne R, Rassart E (18 June 1999). "Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion". Brain Research. Molecular Brain Research. 70 (1): 26–35. doi:10.1016/s0169-328x(99)00123-0. PMID   10381540.
  59. ↑ Ong WY, He Y, Suresh S, Patel SC (July 1997). "Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus". Neuroscience. 79 (2): 359–67. doi:10.1016/s0306-4522(96)00608-2. PMID   9200721. S2CID   11857861.
  60. ↑ Rickhag M, Wieloch T, Gidö G, Elmér E, Krogh M, Murray J, et al. (January 2006). "Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of genes in surviving tissue". Journal of Neurochemistry. 96 (1): 14–29. doi: 10.1111/j.1471-4159.2005.03508.x . PMID   16300643. S2CID   23231070.
  61. ↑ Rickhag M, Deierborg T, Patel S, Ruscher K, Wieloch T (March 2008). "Apolipoprotein D is elevated in oligodendrocytes in the peri-infarct region after experimental stroke: influence of enriched environment". Journal of Cerebral Blood Flow and Metabolism. 28 (3): 551–62. doi: 10.1038/sj.jcbfm.9600552 . PMID   17851453. S2CID   25611779.
  62. ↑ Ganfornina MD, Do Carmo S, Lora JM, Torres-Schumann S, Vogel M, Allhorn M, et al. (August 2008). "Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress". Aging Cell. 7 (4): 506–15. doi:10.1111/j.1474-9726.2008.00395.x. PMC   2574913 . PMID   18419796.
  63. ↑ Do Carmo S, Jacomy H, Talbot PJ, Rassart E (8 October 2008). "Neuroprotective effect of apolipoprotein D against human coronavirus OC43-induced encephalitis in mice". The Journal of Neuroscience. 28 (41): 10330–8. doi:10.1523/JNEUROSCI.2644-08.2008. PMC   6671015 . PMID   18842892.
  64. ↑ Najyb O, Do Carmo S, Alikashani A, Rassart E (August 2017). "Apolipoprotein D Overexpression Protects Against Kainate-Induced Neurotoxicity in Mice". Molecular Neurobiology. 54 (6): 3948–3963. doi:10.1007/s12035-016-9920-4. PMC   7091089 . PMID   27271124.
  65. ↑ Li H, Ruberu K, Muñoz SS, Jenner AM, Spiro A, Zhao H, et al. (May 2015). "Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer's disease mice". Neurobiology of Aging. 36 (5): 1820–33. doi:10.1016/j.neurobiolaging.2015.02.010. PMID   25784209. S2CID   15335129.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.